GlassScriptPhysician profile
Ber-Yuh Yang
NPI 1851397129
$20,529.74
in general payments reported to CMS, 2019-2025
61 companies · $1,796 in 2025
The $1,796 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,364 · 2020: $4,445 · 2021: $3,076 · 2022: $2,831 · 2023: $2,293 · 2024: $2,725 · 2025: $1,796.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,662 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,661.97 |
| Education | $152.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $2,351.35 | 2020-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Amgen INC. | $1,746.25 | 2019-2024 | Prolia, Evenity, Lumakras |
| Gilead Sciences, INC. | $1,340.65 | 2019-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $1,306.86 | 2019-2025 | Opdivo, Reblozyl, Opdualag |
| Merck Sharp & Dohme LLC | $1,136.17 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $1,107.06 | 2019-2025 | |
| Lilly USA, LLC | $933.14 | 2019-2025 | Verzenio, Retevmo, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $885.34 | 2019-2025 | Tagrisso, Enhertu |
| Incyte Corporation | $779.89 | 2019-2025 | Monjuvi, Pemazyre, Jakafi |
| Janssen Biotech, INC. | $627.03 | 2019-2025 | Erleada, Akeega |
| Genentech USA, INC. | $624.87 | 2019-2024 | Tecentriq |
| Novartis Pharmaceuticals Corporation | $608.31 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $588.57 | 2019-2025 | Gilotrif |
| Astellas Pharma US INC | $521.44 | 2019-2025 | Vyloy, Xtandi |
| Pfizer INC. | $463.30 | 2019-2025 |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Puma Biotechnology, INC. | $438.03 | 2019-2024 | Nerlynx |
| Array Biopharma INC | $435.30 | 2020-2025 | Braftovi, Mektovi, Xalkori |
| Eisai INC. | $428.77 | 2022-2025 | |
| Taiho Oncology, INC. | $373.22 | 2019-2025 | |
| Sobi, INC | $311.83 | 2022-2025 | |
| Stryker Corporation | $311.39 | 2022 | |
| Celgene Corporation | $279.50 | 2019-2024 | Pomalyst, Reblozyl |
| Dova Pharmaceuticals | $211.98 | 2020-2021 | |
| Seagen INC. | $204.98 | 2020-2023 | Padcev, Tukysa |
| Alexion Pharmaceuticals, INC. | $202.70 | 2023-2025 | Ultomiris |
| Mirati Therapeutics, INC. | $201.82 | 2023-2024 | Krazati |
| Rigel Pharmaceuticals, INC. | $195.65 | 2022-2023 | Tavalisse, Rezlidhia |
| Emd Serono, INC. | $167.34 | 2023-2025 | Bavencio |
| Daiichi Sankyo INC. | $154.31 | 2024-2025 | Enhertu, Datroway |
| Genzyme Corporation | $140.39 | 2020-2021 | |
| Glaxosmithkline, LLC. | $139.23 | 2020-2021 | |
| Pharmacyclics LLC, An Abbvie Company | $113.79 | 2019 | |
| Deciphera Pharmaceuticals INC. | $105.61 | 2021-2024 | Qinlock |
| Pharmacosmos Therapeutics INC. | $95.64 | 2024 | Cosela |
| G1 Therapeutics, INC. | $90.34 | 2023 | Cosela |
| Teva Pharmaceuticals USA, INC. | $89.16 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $83.74 | 2023-2024 | Orgovyx |
| Tesaro, INC. | $73.50 | 2019 | |
| Agios Pharmaceuticals, INC. | $68.38 | 2025 | Pyrukynd |
| Helsinn Therapeutics (U.S.), INC. | $51.06 | 2019 | |
| Stemline Therapeutics INC. | $44.80 | 2023-2024 | Orserdu |
| Octapharma USA, INC. | $44.70 | 2024 | Octagam Immune Globulin (Human), Panzyga |
| Acrotech Biopharma INC. | $42.32 | 2024 | Beleodaq |
| Jazz Pharmaceuticals INC. | $41.51 | 2020 | |
| Sandoz INC. | $33.75 | 2019 | |
| Exelixis INC. | $29.26 | 2021 | |
| Genmab U.S., INC. | $27.27 | 2024 | Tivdak |
| Aimmune Therapeutics, INC. | $25.00 | 2024 | |
| Blue Earth Diagnostics | $22.89 | 2022 | |
| Corcept Therapeutics | $22.23 | 2025 | Korlym |
| Kyowa Kirin, INC. | $21.69 | 2025 | |
| Sanofi-Aventis U.S. LLC | $21.01 | 2020 | |
| Tempus Ai, INC | $20.73 | 2025 | Xt Cdx |
| Abbvie INC. | $19.74 | 2024 | |
| Springworks Therapeutics, INC. | $19.54 | 2025 | Ogsiveo |
| Kite Pharma, INC. | $18.76 | 2025 | Yescarta |
| Coherus Oncology, INC. | $18.00 | 2025 | Loqtorzi, Udenyca |
| Verastem, INC. | $17.92 | 2019 | |
| Avyxa Pharma, LLC | $17.81 | 2025 | |
| Foundation Medicine, INC. | $17.69 | 2021 | |
| Amneal Pharmaceuticals LLC | $15.23 | 2025 | Alymsys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ber-Yuh Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.